Viibryd, a “revolutionary” antidepressant, hit the market last week. Let’s keep a running journal of your experiences with it. You contribute, I’ll update. Click the image, learn, and participate…
“Tommy’s having a tough time, and they want him on Abilify. I can’t let that happen.” Click on Tommy…
“I’ve heard Viibryd is a 5-HT1A receptor partial agonist. That’s supposed to be a good thing, but I have no clue what it means. Help!” Click the image…
“Viibryd’s out and it’s supposed to be ‘all that.’ But what if it disappoints? Are there other antidepressants on the horizon?” Click the image…
“I am absolutely exhausted, and it’s getting worse. And what’s up with the muscle and joint pain? Something’s terribly wrong here.” Click the image…
